On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end. In 2024, total R&D expenses stood at some 1.78 billion U.S. dollars, an increase from around 1.53 billion dollars in 2022.
* For commercial use only
Basic Account
Starter Account
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Everything on "Small and medium-sized biotech companies" in one document: edited and divided into chapters, including detailed references.
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield
Vice President, Hearst Magazines
Biotech market
SME financing
Research & development
Growth
BioNTech vs. Moderna
Comparison of COVID-19 vaccines
Further related statistics
* For commercial use only
Basic Account
Starter Account
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
